After 3 years of development, Bodytel has released its new patient self management system for metabolic syndrome and diabetes. The system provides ongoing monitoring of parameters for blood sugar, blood pressure, blood coagulation and body weight. The system works with Bluetooth sensors from several leading medical equipment manufacturers that deliver their data to the patient's smartphone.
Lifespot health is currently engaged in ongoing discussions with major companies from the medical device sector about the introduction and further development of the BodyTel infrastructure.
Global home healthcare market projected to reach USD $364Bn by 2022
"We are very proud that we can now start the sales offensive in this huge market"
Major clients like that will be utilising the Bodytel Platform include:
1. B Braun
2. Roche
3. Beurer
Medical Cannabis
Lifespot will also be deploying the Bodytel Platform into the medical marijuana market now, through Cannamed Vaporiser.
BodyTel will monitor not only the dosage of cannabis consumption but also provide additional clinical security via a fingerprint scanner to determine the identity of the user. The BodyTel system will then analyse and present information to carers including clinicians, support services or family members via the iOS, android or web portal formats. Importantly, Lifespot will have the global rights to use this technology in products other than Cannamed.
One such sector is the management of asthma and associated diseases that affect circa 500 million people globally.
Lifespot business
The business is expecting revenues in excess of $350,000 for the January 2018 quarter. With $4,400,000 in cash, there is no requirement for further dilution as the business should become self sustainable and cash flow positive later in the year. While revenue and the business is in its infancy, the Bodytel platform should provide substantial leverage in scaling the business from here on in. Fundamentally this is a very strong business.
(20min delay)